Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.
Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse rates, and significant morbidity and mortality. Apart from advances in radiation therapy, progress in the systemic treatment of SCLC had been stagnant for over three decades despite multiple attempts to develop a...
| Publicado en: | Current Oncology Vol. 30; no. 7; pp. 6289 - 6316 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jul2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=168598404&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 168598404 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jul2023 vid: 30 iid: 7 pid: 97109 pub: MDPI artinfo: ui: 168598404 10.3390/curroncol30070465 168598404 ppf: 6289 ppct: 27 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer. aug: au: Melosky, Barbara L. Leighl, Natasha B. Dawe, David Blais, Normand Wheatley-Price, Paul F. Chu, Quincy S.-C. Juergens, Rosalyn A. Ellis, Peter M. Sun, Alexander Schellenberg, Devin Ionescu, Diana N. Cheema, Parneet K. affil: Department of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC V5Z 4E6, Canada sug: ab: Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse rates, and significant morbidity and mortality. Apart from advances in radiation therapy, progress in the systemic treatment of SCLC had been stagnant for over three decades despite multiple attempts to develop alternative therapeutic options that could improve responses and survival. Recent promising developments in first-line and subsequent therapeutic approaches prompted a Canadian Expert Panel to convene to review evidence, discuss practice patterns, and reach a consensus on the treatment of extensive-stage SCLC (ES-SCLC). The literature search included guidelines, systematic reviews, and randomized controlled trials. Regular meetings were held from September 2022 to March 2023 to discuss the available evidence to propose and agree upon specific recommendations. The panel addressed biomarkers and histological features that distinguish SCLC from non-SCLC and other neuroendocrine tumours. Evidence for initial and subsequent systemic therapies was reviewed with consideration for patient performance status, comorbidities, and the involvement and function of other organs. The resulting consensus recommendations herein will help clarify evidence-based management of ES-SCLC in routine practice, help clinician decision-making, and facilitate the best patient outcomes. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|